Wednesday, June 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “alzheimer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 141
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 141 pipeline programs matching "alzheimer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

141 results for “alzheimer” Back to intelligence hub

Search results

Page 2 of 6
  1. LECANEMAB

    Eisai Co.,

    Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid

    phase 3 small molecule active

    1 trial
  2. Lecanemab

    Eisai Co.,

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial
  3. Levetiracetam NORMON comprimidos recubiertos...

    The George Institute

    Down syndrome, Alzheimer's Disease

    phase 3 small molecule active

    1 trial
  4. NN6535-4725

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial
  5. NN6535-4730

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial
  6. NN6535-7519

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial
  7. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 3 small molecule active

    1 trial
  8. Pioglitazone

    Takeda

    Mild Cognitive Impairment Due to Alzheimer's Disease

    phase 3 small molecule terminated

    2 trials
  9. Remternetug, Placebo to match LY

    Eli Lilly Co.

    Alzheimer’s Disease

    phase 3 small molecule active

    1 trial
  10. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial
  11. VP4896

    Voyager Therapeutics

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial
  12. WN45443

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)

    phase 3 small molecule active

    1 trial
  13. WN45447

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial
  14. bapineuzumab

    Pfizer

    Alzheimer Disease

    phase 3 small molecule terminated

    1 trial
  15. 18F-92

    The First People's Hospital of Lianyungang

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial
  16. 219867

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial
  17. 223646

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial
  18. 5-(1-(2-[18F] fluoroethoxy))-[3-(6 for Alzheimers Disease, sporadic Ce…

    Disc Medicine

    Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson

    phase 2 small molecule active

    1 trial
  19. 64042056ALZ2001

    Janssen-Cilag International N.V.

    Preclinical Alzheimer’s Disease

    phase 2 small molecule active

    1 trial
  20. ABBV-552

    AbbVie

    Alzheimer's Disease (AD)

    phase 2 small molecule completed

    1 trial
  21. ACU193-201

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial
  22. AH0003

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial
  23. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial
  24. ARO-MAPT-SC

    Arrowhead Pharmaceuticals Ireland Limited

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.